A practical reference on HPLC-UV: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-08. Anything still debated is marked as such rather than presented as settled.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
One of the most powerful tools in physical organic chemistry is NMR spectroscopy. An external magnetic field applied to a paramagnetic nucleus generates two discrete states, with positive and negative spin values diverging in energy; the difference in energy can then be probed by determining the frequency of light needed to excite a change in spin state for a given magnetic field. Nuclei that are not indistinguishable in a given molecule absorb at different frequencies, and the integrated peak area in an NMR spectrum is proportional to the number of nuclei responding to that frequency. It is possible to quantify the relative concentration of different organic molecules simply by integration peaks in the spectrum, and many kinetic experiments can be easily and quickly performed by following the progress of a reaction within one NMR sample. Proton NMR is often used by the synthetic organic chemist because protons associated with certain functional groups give characteristic absorption energies, but NMR spectroscopy can also be performed on isotopes of nitrogen, carbon, fluorine, phosphorus, boron, and a host of other elements. In addition to simple absorption experiments, it is also possible to determine the rate of fast atom exchange reactions through suppression exchange measurements, interatomic distances through multidimensional nuclear Overhauser effect experiments, and through-bond spin-spin coupling through homonuclear correlation spectroscopy.
Cyproheptadine, sold under the brand name Periactin among others, is a first-generation antihistamine which is used to treat allergies. In addition, it has a number of off-label uses, such as treatment of serotonin syndrome, insomnia, and use as an appetite stimulant. The drug is taken orally. It is an antihistamine and hence acts as a histamine H1 receptor antagonist. In addition to its antihistamine activity, cyproheptadine has anticholinergic, antiserotonergic, antidopaminergic, and local anesthetic properties. These activities make cyproheptadine useful for various additional uses besides antihistamine indications. As a first-generation antihistamine, cyproheptadine crosses the blood–brain barrier and can produce sedation. The drug can also produce significant central anticholinergic effects at clinically used doses. Cyproheptadine was patented in 1959 and came into medical use in 1961. In 2023, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.
== History == The orexin neuropeptides were discovered in 1998 and the role of the orexin system in the etiology of narcolepsy was identified between 1999 and 2000. Subsequent research further established the role of the orexin system in sleep–wake regulation. Due to the promising potential of orexin system modulation in the treatment of sleep disorders, these findings led to translational efforts to bring orexin receptor modulators to medicine as therapeutic agents. Suvorexant was developed by Merck. It entered clinical development in 2006 and was first described in the medical literature in 2010. The medication was approved by the FDA for the treatment of insomnia in the United States on 13 August 2014. Suvorexant was initially released November 2014 in Japan, then later reached the United States in February 2015, Australia in November 2016, and Canada in November 2018. It was the first orexin receptor antagonist to be introduced for medical use, and was followed by lemborexant in 2019 and daridorexant in 2022. Development of almorexant (ACT-078573) and filorexant (MK-6096) was discontinued, while seltorexant (MIN-202, JNJ-42847922) and vornorexant (ORN-0829, TS-142) are still in clinical trials. Suvorexant marketing exclusivity in the United States was set to expire in January 2023 and patent protection is set to expire in 2029 to 2033.
== Procedure == Dried blood spot specimens are collected by applying a few drops of capillary blood, drawn by lancet from the finger, heel or toe, onto specially manufactured absorbent filter paper. The blood is allowed to thoroughly saturate the paper. It is air dried for several hours. Specimens are stored in low gas-permeability plastic bags with desiccant added to reduce humidity, and may be kept at ambient temperature, even in tropical climates. Once in the laboratory, technicians separate a small disc of saturated paper from the sheet using an automated or manual hole punch, dropping the disc into a flat bottomed microtitre plate. The blood is eluted out in phosphate buffered saline containing 0.05% Tween 80 and 0.005% sodium azide, overnight at 4 °C. The resultant plate containing the eluates forms the "master" from which dilutions can be made for subsequent testing. As an alternative to punching out a paper disc, recent automation solutions extract the sample by flushing an eluent through the filter without punching it out. An automation including the application of an internal standard prior extraction was developed by the Swiss company CAMAG.
The first season of Beast Games, a reality competition show created by Jimmy "MrBeast" Donaldson was first released on Amazon Prime Video on December 19, 2024 and concluded on February 13, 2025. Jeffrey Randall Allen won the season, defeating Twana Barnett. Allen won a total grand prize of $10,000,000.
Sources: en.wikipedia.org
Barq's Cream Soda – clear Big 8 Cream Soda – pink and clear Cott Cream Soda Crush – pink and clear Fanta Jones Soda Kiri Cream Soda – clear Life Brand The Pop Shoppe – also markets a vodka-based alcoholic version President's Choice - clear Walmart Canada – US-style vanilla flavor Some American brands are available in Canada as imports.
== Further reading == Atlas (color) of Chronic Arsenic Poisoning (2010), Nobuyuki Hotta, Ichiro Kikuchi, Yasuko Kojo, Sakuragaoka Hospital, Kumamoto, ISBN 978-4-9905256-0-6. A 2011 article in the journal Social Medicine discusses community interventions to combat arsenic poisoning: Beyond medical treatment, arsenic poisoning in rural Bangladesh. D. J. Vaughan and D. A. Polya (2013): Arsenic – the great poisoner revisited. Elements 9, 315–316. PDF (update on the world situation in 2013)
Ubiquitin-binding domains (UBDs) are modular protein domains that non-covalently bind to ubiquitin, these motifs control various cellular events. Detailed molecular structures are known for a number of UBDs, binding specificity determines their mechanism of action and regulation, and how it regulates cellular proteins and processes.
=== Campaigns === On November 8, 1980, Sanders announced his candidacy for mayor. He formally announced his campaign on December 16 at a City Hall press conference. Sanders selected Linda Niedweske as his campaign manager. The Citizens Party attempted to nominate Greg Guma for mayor, but Guma declined, saying it would be "difficult to run against another progressive candidate". Sanders had been convinced to run for the mayoralty by his close friend Richard Sugarman, an Orthodox Jewish professor of religious studies at the University of Vermont, who had shown him a ward-by-ward breakdown of the 1976 Vermont gubernatorial election, in which Sanders had run, that showed him receiving 12% of the vote in Burlington despite only getting 6% statewide. Sanders initially won the mayoral election by 22 votes against incumbent mayor Gordon Paquette, Richard Bove, and Joseph McGrath, but the margin was later reduced to 10 votes. Paquette did not contest the results of the recount. Paquette did not campaign or promote his candidacy since neither Sanders nor Bove was seen as a serious challenger. Sanders had not previously won an election. Paquette was also considered to have lost because he proposed an unpopular $0.65 per $100 raise in taxes that Sanders opposed. Sanders spent around $4,000 on his campaign. Sanders criticized the pro-development incumbent as an ally of prominent shopping center developer Antonio Pomerleau, while Paquette warned of ruin for Burlington if Sanders were elected.
2 NH3 + H2SO4 → [NH4]2SO4 A mixture of ammonia gas and water vapor is introduced into a reactor that contains a saturated solution of ammonium sulfate and about 2% to 4% of free sulfuric acid at 60 °C (140 °F). Concentrated sulfuric acid is added to keep the solution acidic, and to retain its level of free acid. The heat of reaction keeps reactor temperature at 60 °C (140 °F). Dry, powdered ammonium sulfate may be formed by spraying sulfuric acid into a reaction chamber filled with ammonia gas. The heat of reaction evaporates all water present in the system, forming a powdery salt. Approximately 6,000 million tons were produced in 1981. Ammonium sulfate also is manufactured from gypsum (CaSO4·2H2O). Finely divided gypsum is added to an ammonium carbonate solution. Calcium carbonate precipitates as a solid, leaving ammonium sulfate in the solution.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.